Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 4,864 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 4,864 shares of Relay Therapeutics stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $2.84, for a total transaction of $13,813.76. Following the sale, the chief financial officer now directly owns 374,567 shares of the company’s stock, valued at $1,063,770.28. The trade was a 1.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, January 30th, Thomas Catinazzo sold 20,791 shares of Relay Therapeutics stock. The shares were sold at an average price of $4.42, for a total transaction of $91,896.22.
• On Tuesday, January 28th, Thomas Catinazzo sold 36,036 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.63, for a total transaction of $166,846.68.

Relay Therapeutics Stock Down 3.7 %

Shares of NASDAQ:RLAY traded down $0.10 during trading on Monday, hitting $2.62. The stock had a trading volume of 2,950,837 shares, compared to its average volume of 1,868,152. Relay Therapeutics, Inc. has a 12-month low of $2.47 and a 12-month high of $10.72. The stock has a market capitalization of $444.15 million, a price-to-earnings ratio of -1.00 and a beta of 1.65. The stock has a 50-day simple moving average of $3.84 and a two-hundred day simple moving average of $4.96.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. As a group, sell-side analysts forecast that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC raised its holdings in shares of Relay Therapeutics by 160.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 6,500 shares of the company’s stock valued at $27,000 after buying an additional 4,000 shares during the period. Stifel Financial Corp purchased a new stake in shares of Relay Therapeutics during the 4th quarter worth approximately $42,000. Twinbeech Capital LP purchased a new position in shares of Relay Therapeutics during the fourth quarter worth about $42,000. Cibc World Markets Corp purchased a new position in Relay Therapeutics during the 4th quarter worth approximately $47,000. Finally, Summit Investment Advisors Inc. raised its position in Relay Therapeutics by 41.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 12,730 shares of the company’s stock valued at $52,000 after purchasing an additional 3,760 shares during the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on RLAY shares. Stifel Nicolaus reduced their price objective on shares of Relay Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Relay Therapeutics in a report on Friday, March 7th. The Goldman Sachs Group lowered their price objective on shares of Relay Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $21.00 target price on shares of Relay Therapeutics in a report on Thursday, December 12th. Finally, Leerink Partners cut their target price on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Relay Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $19.80.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.